<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497338</url>
  </required_header>
  <id_info>
    <org_study_id>new anticoagulation of ECMO</org_study_id>
    <nct_id>NCT03497338</nct_id>
  </id_info>
  <brief_title>New Anticoagulation Strategies of VV-ECMO</brief_title>
  <official_title>the Efficacy and Safety of New Anticoagulation Strategies of Maintain Normal Clot Rate to Prevent Hemorrhage While VV-ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiao Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effective and normative anticoagulation is one of the most important components of&#xD;
      Extracorporeal membrane oxygenation (ECMO) management. Excessive anticoagulation may lead to&#xD;
      hemorrhage, which is the most common and serious complication. Currently, the most common&#xD;
      factors for monitoring anticoagulation of ECMO are the activated clotting time (ACT) and&#xD;
      activated partial thromboplastin time (APTT). However, there is a lack of a unified&#xD;
      understanding of the related monitoring measures, monitoring targets, and bleeding risk&#xD;
      assessments, which have been chosen mainly because of experiences reported by various ECMO&#xD;
      centers or the results of retrospective studies.Therefore, anticoagulation strategies need to&#xD;
      be improved. Our research have found ECMO anticoagulation management should be transformed&#xD;
      from monitoring only the APTT/activated clotting time (ACT) to considering the entire&#xD;
      coagulation process. To maintain thrombosis ability and PLT function within normal ranges may&#xD;
      help reduce hemorrhage rates and improve prognoses. This randomized controlled study aim to&#xD;
      develop the safety and efficacy new anticoagulation strategies of VV-ECMO.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Percentage of Participants with hemorrhage events</measure>
    <time_frame>4 weeks</time_frame>
    <description>1) fatal bleeding; 2) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; and/or 3. bleeding causing a drop in hemoglobin level by 20 g/L or more or requiring transfusion of two units of whole blood or red cells.</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Hemorrhage</condition>
  <eligibility>
    <study_pop>
      <textblock>
        the patients received ECMO support&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age more than 18 years old, VV-ECMO is estimated more than 3 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemorrhage before VV-ECMO established, VV-ECMO more than 48 hours before admitted,&#xD;
             VV-ECMO is estimated less than 3 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of respiratory and critical care medicine,Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Tang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

